The content on this site is intended for healthcare professionals only
ASCO GU 2026: Updates in renal cancer
ASCO GU 2026: Updates in bladder cancer
ASCO GU 2026: Updates in metastatic prostate cancer
ASCO GU 2026: Updates in localised prostate cancer
Post-orchiectomy miR-371 predicts recurrence in clinical stage I testicular germ cell tumours during active surveillance
Real-world outcomes after post-Lu177 therapy in mCRPC show limited survival and heterogeneous treatment patterns
Evaluation and definition of response and progression from trials to clinical practice
FX-909 shows tumour regression in PPARG-high advanced urothelial carcinoma
Enfortumab vedotin and pembrolizumab improves EFS, OS, and pCR in muscle-invasive bladder cancer
Epcoritamab plus rituximab and lenalidomide improves efficacy in relapsed or refractory follicular lymphoma
The Vanessa Moss Prize: celebrating research into cancer health disparities
Climate and environmental factors drive seasonal risk of invasive mucormycosis in haematologic malignancies
